Lupin to invest $250 million in US manufacturing

India-headquartered Lupin (BSE: 500257) has announced its plans for a new state-of-the-art pharmaceutical manufacturing plant in Coral Springs, USA.

With a projected cumulative investment of $250 million, including research and development, infrastructure and capital expenditures over a five-year period, the new site will have the capacity to accommodate the production of more than 25 critical respiratory medicines, including lifesaving albuterol inhalers for children with asthma and service members at home and overseas.

This investment in US manufacturing will create over 1,000 construction jobs and over 200 long-term skilled manufacturing jobs by 2030 and strengthen domestic manufacturing and enhance supply chain diversification. The new facility will have the capacity to produce more than 25 critical respiratory medicines and inhalers.